Accessibility Menu
NovaBay Pharmaceuticals logo

NovaBay Pharmaceuticals(NYSEMKT) NBY

Market Cap$55.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-100%
5 Year-100%
1 Year-49%
1 Month-1%
$1.11
+0.91%
+0.01Today
NovaBay Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 1.102026-07-24
NovaBay Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12%USD 1.252026-07-17
1 month-0.9%USD 1.112026-06-24
3 month-17.29%USD 1.332026-04-24
Year to date-96.1%USD 28.202025-12-31
1 year-48.9%USD 2.152025-07-24
3 year-98.7%USD 84.732023-07-25
5 year-99.96%USD 2,562.852021-07-23
Since inception-100%USD 366,410.642007-10-26

NovaBay Pharmaceuticals Financials at a Glance

Market Cap

$55.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.46M

Net Income (TTM)

$522.59M

EPS (TTM)

-$7.43

P/E Ratio

-0.15

Dividend

$0.00

Beta (Volatility)

0.77 (Low)

Price

$1.11

Volume

63,331.152

Open

$1.15

Previous Close

$1.12

Daily Range

$1.10 - $1.18

52-Week Range

$1.01 - $99.75

Estimated Earnings Date

Apr 1, 2026

NBY News

Avoid This Drug Stock

CAPS' Weekly Top Stock IdeaJan 19, 2012

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NovaBay Pharmaceuticals

NovaBay makes products for eye and skin care, helping people manage daily hygiene and skin conditions. Its solutions clean eyelids and treat common skin issues like acne or eczema. The company now focuses on holding digital assets, moving away from traditional healthcare products.

Products and Services

  • Eyecare Solutions: Avenova cleans eyelids and skin around the eyes; represented the majority of revenue prior to divestiture in January 2025.
  • Wound Care: NeutroPhase and PhaseOne helped clean wounds and prevent infection; represented a small portion of 2024 revenue.
  • Skincare Products: DERMAdoctor addressed acne, eczema, and other skin concerns; represented a small portion of 2024 revenue.
  • Digital Asset Holdings: Now holds and manages SKY tokens, representing about 90% of total assets as of March 2026.

Growth and Expansion

  • Sold Avenova brand to PRN Physician Recommended Nutriceuticals in January 2025.
  • Sold PhaseOne and NeutroPhase to Phase One Health LLC in January 2025.
  • Sold DERMAdoctor business in March 2024 to an undisclosed buyer.
  • Raised $137.4 million in January 2026 through a private placement, shifting focus to digital assets.
  • Entered a $100 million at-the-market equity program in January 2026, raising $13.5 million by March 2026.

What Makes NovaBay Stand Out

NovaBay shifted from healthcare products to digital asset management in 2025. Its SKY token holdings now dominate its balance sheet. The company uses U.S.-based custodians for digital asset security and regulatory compliance.

Five Things You Need to Know

  • Revenue was $521,000 in Q3 2025, down 78.7% from Q3 2024.
  • Operating loss was $8.4 million in 2025, up 14% from 2024.
  • Net loss from continuing operations was $33.2 million in 2025.
  • SKY tokens made up about 90% of assets by March 2026.
  • Employee count dropped to 4 by December 2025 after business realignment.

Bottom Line

NovaBay transformed from a healthcare product maker to a digital asset holding company. Its future now depends on managing and securing blockchain-based assets.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

14

CEO

Michael Kazley

Website

www.novabay.com

Headquarters

EmeryVille, CA 94608, US

NBY Financials

Key Financial Metrics (TTM)

Gross Margin

-3.45%

Operating Margin

-213.93%

Net Income Margin

21217.70%

Return on Equity

1715.13%

Return on Capital

N/A

Return on Assets

290.74%

Earnings Yield

-6.67%

Dividend Yield

0.00%

Payout Ratio

0.92%

Stock Overview

Market Cap

$55.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

50.45M

Volume

63.33K

Avg. Volume

791.04K

Financials (TTM)

Gross Profit

-$38.00K

Operating Income

-$4.68M

EBITDA

-$4.56M

Operating Cash Flow

-$8.87M

Capital Expenditure

$0.00

Free Cash Flow

-$8.87M

Cash & ST Invst.

$18.41M

Total Debt

$637.00K

NovaBay Pharmaceuticals Performance Analysis

NovaBay Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 14,404,00041.2%
20232023-12-31USD 10,455,000-27.4%
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
NovaBay Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31-200.0%
Q12026-03-31572.7%
NovaBay Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1,767.9392.1%
20232023-12-31USD -550.08-68.9%
20242024-12-31USD -12.68-97.7%
20252025-12-31USD -110.31770.1%
NovaBay Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-123.2%
Q32025-09-3033.3%
Q42025-12-31-10513.6%
Q12026-03-31171.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.46M

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$55.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.27M

N/A

Employees

13

N/A

Net Income

$552.40M

+7102.1%

EBITDA

-$385.00K

+88.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$18.41M

+117.4%

Total Debt

$637.00K

-43.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$166.00K

-74.0%

Short Term Debt

$471.00K

-3.3%

Return on Assets

2.91%

N/A

Return on Invested Capital

-2.99%

N/A

Free Cash Flow

-$1.80M

-36.3%

Operating Cash Flow

-$1.80M

-36.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VYNEVYNE Therapeutics Inc.
$28.56+12.22%
QNRXQuoin Pharmaceuticals, Ltd.
$4.29+0.23%
RADXRadiopharm Theranostics Limited
$3.66+3.10%
TCRTAlaunos Therapeutics, Inc.
$1.93-0.52%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About NBY

What is the current price of NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals is trading at $1.12 per share.

What is the 52-week range for NovaBay Pharmaceuticals?

Over the past 52 weeks, NovaBay Pharmaceuticals has traded between $1.01 and $99.75.

How much debt does NovaBay Pharmaceuticals have?

As of the most recent reporting period, NovaBay Pharmaceuticals reported total debt of $637.00K.

How much cash does NovaBay Pharmaceuticals have on hand?

NovaBay Pharmaceuticals reported $18.41M in cash and cash equivalents in its most recent financial results.

What is NovaBay Pharmaceuticals’s dividend yield?

NovaBay Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services